Merck Rests Its Case in Vioxx Trial
8th Dec 2005, 08:57 GMT
By ANGELA K. BROWN HOUSTON - Merck & Co. rested its case Wednesday in the first federal trial involving the painkiller Vioxx after a pathologist testified that the drug played no role in a man's fatal heart attack.
Merck Rests Its Case in Vioxx Trial related news:
- Merck Rests Its Case in Vioxx Trial — ABC News: Business
- Merck rests its defense case in Vioxx trial — New Jersey News
- Merck Rests Case in Vioxx Trial — WSJ.com: US Business
- Merck rests case in federal Vioxx trial — NewsOk.com - Business
- Defense Rests in Federal Vioxx Trial — FOXNews.com - Business
- Jury to Deliberate in Vioxx Trial — WSJ.com: What's News US
- Vioxx retrials for Merck? — CNNmoney.com Recently Published/Updated
- Jurors in Vioxx trial deliberate two hours without verdict — Breaking Business (AP)
- Merck deleted Vioxx safety info: Journal — KeralaNext: Latest News
- Texas jury gets federal Merck Vioxx case — Reuters: US Domestic News
Latest news from RedOrbit News - Health:
- Pet Shop Boys Fans Know Better _ Why Bother Sharing?
- Corcept Tests Psych. Major Depression Rx
- On Its 30th Anniversary, Smokeout Provides Even More Help Quitting Smoking
- Health Plans and Disease Management Companies Are Seeking To Reduce the Use of the ER for Non-Urgent Care - Urgent Emergency Room Usage October 18, 2006 Audio Conference on CD-ROM
- Invitation Conference Call Analyst Meeting
- As Benefit Costs Rise, Employee Retirement Savings Decline
- Aetna to Help Members Quit Tobacco With New Tobacco Cessation Program
- Lilly: Arxxant Cuts Sight Loss in Diabetes
- SW Doctors PA Launch Affordable Primary Care (APC) Services
- Health Savings Technology Appoints New Management Team to Spearhead Growth in Customer-Directed Healthcare Industry